Background: Subcutaneous trastuzumab (T-SC) administration does not allow the historical
target concentration of 20 µg/mL for efficacy to be reached, from the start of treatment in …

La Investigación Aplicada en un entorno clínico ha de ser aquella que aporte soluciones a
los problemas cotidianos de los sanitarios. Esto requiere de un cambio en la forma de …

Background: Endoscopic balloon dilation represents a valid therapeutic alternative in
patients with inflammatory bowel disease that have colonic symptomatic strictures weather …

Objective Tyrosine kinase inhibitors (TKIs) have successfully changed the natural course of
chronic myeloid leukaemia (CML). Although they are highly effective drugs, their clinical …

Objective The present work analyzed the stability of trastuzumab concentrations in blood
and plasma samples stored at 4° C and–; 20° C. Method Blood samples of patients treated …

Background/Aim: L-Asparaginase (L-ASNase) is used as a tumor-inhibitory drug on
paediatric acute lymphoblastic leukemia (ALL). ERW-ASNase is commercialised as a …

Introduction The addition of imatinib to the therapeutic arsenal for chronic myeloid
leukaemia (CML) has changed the natural course of the disease, in such a way that it is now …

Asparaginase (ASNase) use as a tumour-inhibitor drug has changed completely the natural
course of paediatric acute lymphoblastic leukaemia (ALL) in such a way that it represents a …

Introduction Patient-reported outcomes (PROs) use, via a computer registry, allows patients
to report their symptoms enabling the detection of early signs of progression of the disease …

Objectives Imatinib is the first therapeutic option for the treatment of unresectable or
metastatic gastrointestinal stromal tumours. Previous studies have shown an improvement in …